-
已有(3)人發表了評論
- 回復 舉報 [ 2樓 fastest ] 發表於
- Zanubrutinib, sold under the brand name Brukinsa, is for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy. It was approved for medical use in the United States in 2019. The U.S. Food and Drug Administration (FDA) granted Brukinsa breakthrough therapy designation and orphan drug designation. The FDA granted approval of Brukinsa to BeiGene USA